Clinical trials with oncolytic measles virus

Current status and future prospects

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

Original languageEnglish (US)
Pages (from-to)177-187
Number of pages11
JournalCurrent Cancer Drug Targets
Volume18
Issue number2
DOIs
StatePublished - Jan 1 2018

Fingerprint

Oncolytic Viruses
Measles virus
Clinical Trials
Breast Neoplasms
Viruses
Carcinoembryonic Antigen
Mesothelioma
Neurilemmoma
Glioblastoma
Head and Neck Neoplasms
Multiple Myeloma
Ovarian Neoplasms
Vaccines
Neoplasms
sodium-iodide symporter

Keywords

  • Cancer gene therapy
  • Measles virus clinical trials
  • MV-CEA
  • MV-NIS
  • Oncolytic measles
  • Virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Cancer Research

Cite this

Clinical trials with oncolytic measles virus : Current status and future prospects. / Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela; Peng, Kah-Whye; Federspiel, Mark J; Russell, Stephen J; Galanis, Evanthia.

In: Current Cancer Drug Targets, Vol. 18, No. 2, 01.01.2018, p. 177-187.

Research output: Contribution to journalReview article

@article{1435d04662c14f928299a056e72a75d3,
title = "Clinical trials with oncolytic measles virus: Current status and future prospects",
abstract = "Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.",
keywords = "Cancer gene therapy, Measles virus clinical trials, MV-CEA, MV-NIS, Oncolytic measles, Virotherapy",
author = "Pavlos Msaouel and Mateusz Opyrchal and Angela Dispenzieri and Kah-Whye Peng and Federspiel, {Mark J} and Russell, {Stephen J} and Evanthia Galanis",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1568009617666170222125035",
language = "English (US)",
volume = "18",
pages = "177--187",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Clinical trials with oncolytic measles virus

T2 - Current status and future prospects

AU - Msaouel, Pavlos

AU - Opyrchal, Mateusz

AU - Dispenzieri, Angela

AU - Peng, Kah-Whye

AU - Federspiel, Mark J

AU - Russell, Stephen J

AU - Galanis, Evanthia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

AB - Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

KW - Cancer gene therapy

KW - Measles virus clinical trials

KW - MV-CEA

KW - MV-NIS

KW - Oncolytic measles

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=85021206999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021206999&partnerID=8YFLogxK

U2 - 10.2174/1568009617666170222125035

DO - 10.2174/1568009617666170222125035

M3 - Review article

VL - 18

SP - 177

EP - 187

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 2

ER -